Loading
A phase 2 trial of Velzatinib in advanced solid tumours, run by GlaxoSmithKline, now recruiting.
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib is a phase 2 interventional study registered as NCT07689201 by GlaxoSmithKline, with 24 participants planned, started 2026-08-17 and due to reach its primary completion in 2027-11-29. Interventions recorded: Velzatinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/